Development of pharmacotherapies for drug addiction: a Rosetta stone approach. - Test2 - elhamkhani - TriplyDB

Development of pharmacotherapies for drug addiction: a Rosetta stone approach.

Development of pharmacotherapies for drug addiction: a Rosetta stone approach.

http://www.wikidata.org/entity/Q37383571

about

Natural rewards, neuroplasticity, and non-drug addictions Acamprosate: a prototypic neuromodulator in the treatment of alcohol dependence Proteomic investigation of epigenetics in neuropsychiatric disorders: a missing link between genetics and behavior?R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse Neurocircuitry of addiction Negative Allosteric Modulators of Metabotropic Glutamate Receptors Subtype 5 in Addiction: a Therapeutic Window Animal studies of addictive behavior 15 years of genetic approaches in vivo for addiction research: Opioid receptor and peptide gene knockout in mouse models of drug abuse Novel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulation Addiction and the brain-disease fallacy Cocaine is low on the value ladder of rats: possible evidence for resilience to addiction Preclinical studies of alcohol binge drinking Pharmacotherapeutic agents in the treatment of methamphetamine dependence.Predicting extinction and reinstatement of alcohol and sucrose self-administration in outbred rats.The dopamine D3 receptor partial agonist CJB090 and antagonist PG01037 decrease progressive ratio responding for methamphetamine in rats with extended-access.The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence.Amygdala 14-3-3ζ as a novel modulator of escalating alcohol intake in mice.Attenuation of cocaine-induced locomotor activity in male and female mice by active immunization.Neurobiology of addiction: a neurocircuitry analysis.Inhalation of Alcohol Vapor: Measurement and Implications.The use-dependent, nicotinic antagonist BTMPS reduces the adverse consequences of morphine self-administration in rats in an abstinence model of drug seeking Operant sensation seeking in the mouse.Inhibition of aldehyde dehydrogenase-2 suppresses cocaine seeking by generating THP, a cocaine use-dependent inhibitor of dopamine synthesis.Development of mechanical hypersensitivity in rats during heroin and ethanol dependence: alleviation by CRF₁ receptor antagonism.Experimental psychiatric illness and drug abuse models: from human to animal, an overview Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse.Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis.Analgesia or addiction?: implications for morphine use after spinal cord injury.Aripiprazole for relapse prevention and craving in alcohol use disorder: current evidence and future perspectives.Glucocorticoid receptor antagonism decreases alcohol seeking in alcohol-dependent individuals.Pharmacogenetic approaches to the treatment of alcohol addiction.Theoretical frameworks and mechanistic aspects of alcohol addiction: alcohol addiction as a reward deficit disorder.Medications development to treat alcohol dependence: a vision for the next decade.Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse.Upregulation of nerve growth factor in central amygdala increases sensitivity to opioid reward Discovery, Development, and Adoption of Medications to Treat Alcohol Use Disorder: Goals for the Phases of Medications Development Phosphoproteomic Analysis Reveals a Novel Mechanism of CaMKIIα Regulation Inversely Induced by Cocaine Memory Extinction versus Reconsolidation A selective insular perfusion deficit contributes to compromised salience network connectivity in recovering alcoholic men.Focus on: Neuroscience and treatment: the potential of neuroscience to inform treatment.An efficient early phase 2 procedure to screen medications for efficacy in smoking cessation.

P2860

Q22251254-19CFE604-822E-46B4-AA41-B30D7A17E9E4 Q24595863-7496960A-4F9D-4AAF-89E4-3240A7F5ECE5 Q24603107-905A9EC5-4CAF-40B6-AF82-CF13D35FB617 Q24621917-A3545AA0-88D5-440A-B197-58E8819B7BAC Q24647156-3082B232-4DA8-4C8E-A942-B39177C370FB Q26775243-2DE63291-3423-4C3A-B077-7E5B4E9CD02F Q26823154-126D3BB6-AE19-4ECF-AD5A-16DB3C857F23 Q26824667-57CD0AD7-ECAF-4EA9-8C2C-2F66C5CDB7AB Q26853630-183A69FD-01E0-4B66-BBB9-929DEA2373B7 Q26865252-3E720620-D4A3-4A39-92C9-F33A37F83B72 Q28474933-40957FEA-752D-4B8B-83A4-249169D9B10A Q28741039-2E93C365-4F55-41BA-AF1B-F28413FE602F Q30235058-924D708A-0613-498A-AD23-EE4C1C2BEEBB Q33693932-7C2662B0-11B2-472F-82FF-92E3F0811BEB Q33992366-3A502BE0-39D9-413C-B9E7-06F3176267EE Q34088940-7839E7A7-D3D2-496D-9307-F05F144EAE69 Q34282208-55F84935-B0C3-4FC4-B5C7-6CC724368315 Q34287658-2E32AE99-0997-4AB8-8FEF-D19224FC2D7F Q34535855-8465AA30-3AD5-4703-A7A8-472D9DE96A7E Q34548568-60728542-2AA0-4391-A5C5-28948946B0AC Q35087497-F34F3F26-F2FD-490A-9F07-2A828BB82F6B Q35175178-EF2F2028-FCEB-474B-923F-08EB7B1BBE65 Q35320772-A68E6A07-CE19-4D24-988F-59A131790019 Q35685680-C07631EA-DCB6-4ABD-B5BD-D112BBCE378D Q35774481-068F32A4-BBC9-4976-B279-2A6FF736CF0A Q35881015-398A9C9A-6308-4D35-9ED8-93508E600DC2 Q35892818-8E88523F-F274-4D38-BC82-875AB8554598 Q35964829-4D1192D0-96F8-4AA2-9240-9B97484E788B Q35995252-2632E240-9AEA-43B3-BFC4-8F02DC8BAEA4 Q36040481-73C4F138-2146-4D6D-99BD-A4B3984EB501 Q36126591-BA6843BD-511E-4AAC-A666-C44FD22FBDFA Q36253073-2EA4C091-3BAC-4C8A-91D2-940889FB6F51 Q36357552-4298ABE0-AE87-4A7D-AE0F-4004B2324ABC Q36372867-FF48A168-A67C-40AD-A219-175D1AA43B73 Q36403790-CB36DA7C-7D3D-4FD6-942F-48BEADB81B0E Q37059221-E55CD4C1-4C00-4BEF-851A-1E841E1AC09A Q37110576-286C1BE4-8869-4138-9ADA-130F76E71D10 Q37154429-406A5123-6A1E-456D-981D-F4B5F5CD5941 Q37460503-00FD625B-EC7D-4ED4-8D2E-9C748B37F174 Q37543473-1FB45ACE-CBBA-4769-93A9-295283C7F606

P2860

Development of pharmacotherapies for drug addiction: a Rosetta stone approach.

http://www.wikidata.org/entity/Q37383571

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Development of pharmacotherapies for drug addiction: a Rosetta stone approach.

@en

Development of pharmacotherapies for drug addiction: a Rosetta stone approach.

@nl

type

label

Development of pharmacotherapies for drug addiction: a Rosetta stone approach.

@en

Development of pharmacotherapies for drug addiction: a Rosetta stone approach.

@nl

prefLabel

Development of pharmacotherapies for drug addiction: a Rosetta stone approach.

@en

Development of pharmacotherapies for drug addiction: a Rosetta stone approach.

@nl

P1433

Q37383571-BD079EA3-9329-4EBE-90F7-8FFE5E597731

P1476

Q37383571-7BA462F3-3FF3-4C94-BCA7-AABF987B2706

P2093

Q37383571-08851A59-E667-4533-B6F3-DAD010E2384F

Q37383571-9912EAE7-4013-4060-AD18-54C0C59CB3DA

Q37383571-D0A69EEF-C95C-469E-A7F0-C98C453221B6

P2860

Q37383571-020EC717-FC0C-45AD-9DF4-2336EA1B23FD

Q37383571-027A30D6-7C36-4728-83BA-6200FCFDFEB2

Q37383571-055F1782-6FE7-4D43-8A76-E4551807068F

Q37383571-073E10A5-0265-4D3E-89E3-4B838803DA72

Q37383571-076CF727-1CCF-4D68-A56B-0498840FE499

Q37383571-0827B77C-3A83-455B-AB07-1DFC6A2A56B0

Q37383571-0913F739-44F0-4F56-B1F5-5178A8009F66

Q37383571-0B1183CB-8322-4DC2-BB90-AF3B1331E983

Q37383571-0CC5B171-7FC7-4473-97FB-56B6C0A312E7

Q37383571-0F1FE561-6F4E-4322-B827-615627550FCB

P2888

Q37383571-FBE2BAAF-0466-4B9C-BDEA-3260B1E0B6FA

P304

Q37383571-776C3317-EE80-4F92-B0B5-3BF5D6A2F3EC

P31

Q37383571-63042A9F-EE5F-4125-A4C0-B5BE322A0302

P356

Q37383571-4284FECD-36C7-4643-B1A5-E3E6C23227BA

P433

Q37383571-0F67226C-5B50-4F09-BB11-A016B1943BF8

P478

Q37383571-3075E395-7A95-453C-888A-93C93704C706

P577

Q37383571-1EEDD8B7-B6EC-4510-B9B5-2A615C2CB8C0

P5875

Q37383571-00846CE6-EA9B-43CA-A9EA-DABAAC77E0FE

P698

Q37383571-02CA8755-3F54-440F-811E-17DDDF6D0C0C

P921

Q37383571-C9333763-507C-4ECA-993F-F4F3B03B01E0

Q37383571-F3D064FB-CAE0-4FF9-BF3B-4535675749ED

P932

Q37383571-E92CB996-21F3-4988-9A0C-197A26B7365C

P356

P1433

Nature Reviews Drug Discovery

P1476

Development of pharmacotherapies for drug addiction: a Rosetta stone approach.

@en

P2093

Barbara J Mason

http://www.w3.org/2001/XMLSchema#string

G Kenneth Lloyd

http://www.w3.org/2001/XMLSchema#string

George F Koob

http://www.w3.org/2001/XMLSchema#string

P2860

Multiple Dopamine Functions at Different Time Courses

Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction

Stress, dysregulation of drug reward pathways, and the transition to drug dependence

Impulsivity as a determinant and consequence of drug use: a review of underlying processes

An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study

Positive modulation of GABA(B) receptors decreased nicotine self-administration and counteracted nicotine-induced enhancement of brain reward function in rats

A role for brain stress systems in addiction.

The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system

Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence

Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses

P2888

P304

500-515

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRD2828

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26254593

http://www.w3.org/2001/XMLSchema#string

P698

19483710

http://www.w3.org/2001/XMLSchema#string

P921

substance dependence

pharmacotherapy

P932

2760328

http://www.w3.org/2001/XMLSchema#string